Newest figures come from the 20-F for FY2024, filed Apr 30, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PRTC SEC filings page.
PureTech Health plc American (PRTC) reported $4.8M in revenue for fiscal year 2024, up 45.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
PureTech’s reported profit is not yet an operating cash engine, while its asset-heavy balance sheet carries relatively little debt.
FY2024 paired net income of$27.8M with operating cash flow of-$134.4M , so accounting profit did not translate into cash from operations. Free cash flow was also-$134.4M while capital expenditure was only$11K , indicating that the cash use is not primarily a conventional facilities-reinvestment burden.
Revenue rose
Long-term debt was
Financial Health Signals
Scored against operating companies for FY2024. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of PureTech Health plc American's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. PureTech Health plc American scores 9/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. PureTech Health plc American scores 1/100 on it among other operating companies.
PureTech Health plc American carried $0.04 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2024, a debt-to-equity ratio of 0.04. With no EBITDA figure for fiscal year 2024, PureTech Health plc American is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 87/100 among other operating companies measured the same way.
PureTech Health plc American held $9.33 of current assets for every $1 of current liabilities at the end of fiscal year 2024, a current ratio of 9.33. Liquidity ranks operating companies on that ratio, and PureTech Health plc American scores 97/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. PureTech Health plc American scores 1/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. PureTech Health plc American scores 28/100 on it among other operating companies.
PureTech Health plc American passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
For every $1 of reported earnings, PureTech Health plc American used $4.84 of operating cash (-$134.4M OCF vs $27.8M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
PureTech Health plc American generated $4.8M in revenue in fiscal year 2024. This represents an increase of 45.0% from the prior year.
PureTech Health plc American reported $27.8M in net income in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Cash & Balance Sheet
PureTech Health plc American recorded an outflow of $134.4M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
PureTech Health plc American held $280.6M in cash against $14.7M in long-term debt as of fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
PureTech Health plc American's ROE was 6.8% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 21.3 percentage points from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not shown for fiscal year 2024: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
PureTech Health plc American spent $4.8M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 75.6% from the prior year.
PureTech Health plc American invested $11K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 84.3% from the prior year.
Not reported for fiscal year 2024.
PRTC Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|
| Revenue | $4.8M+45.0% | $3.3M-78.7% | $15.6M-10.2% | $17.4M+47.8% | $11.8M+20.0% | $9.8M-52.7% | $20.7M |
| Interest Expense | $1.3M-16.1% | $1.5M-22.1% | $2.0M-9.1% | $2.2M-7.3% | $2.4M-5.7% | $2.5M-90.4% | $25.9M |
| Income Tax | -$4.0M-113.1% | $30.5Mn/m | -$55.7M-1583.5% | $3.8M-73.9% | $14.4M-87.2% | $112.4M+4961.2% | $2.2M |
| Net Income | $27.8Mn/m | -$66.6Mn/m | -$37.1Mn/m | -$62.7M-1472.8% | $4.6M-98.8% | $366.1Mn/m | -$70.7M |
| Diluted Shares (Avg) | 256M-7.3% | 276M-3.0% | 285M-0.6% | 287M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted).
PRTC Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|
| Total Assets | $602.6M-13.2% | $694.0M-1.2% | $702.6M-25.7% | $946.0M-4.4% | $990.0M+5.2% | $941.2M | N/A |
| Current Assets | $386.3M+11.2% | $347.2M-10.1% | $386.2M-23.0% | $501.8M+21.1% | $414.3M+145.4% | $168.8M | N/A |
| Cash & Equivalents | $280.6M+46.9% | $191.1M+27.5% | $149.9M-67.8% | $465.7M+15.3% | $403.9M+205.1% | $132.4M+13.1% | $117.1M |
| Accounts Receivable | $1.5M-35.9% | $2.4M-80.0% | $11.9M+273.9% | $3.2M+24.1% | $2.6M+29.4% | $2.0M | N/A |
| Total Liabilities | $194.7M-17.4% | $235.7M+52.0% | $155.1M-57.1% | $361.9M+7.6% | $336.5M+15.7% | $290.8M | N/A |
| Current Liabilities | $41.4M-19.4% | $51.4M-47.0% | $96.9M-57.2% | $226.1M+25.0% | $180.9M+30.0% | $139.2M | N/A |
| Non-Current Liabilities | $153.3M-16.8% | $184.4M+216.9% | $58.2M-57.1% | $135.7M-12.7% | $155.5M+2.6% | $151.6M | N/A |
| Long-Term Debt | $14.7M-19.6% | $18.3M-24.4% | $24.2M-16.8% | $29.0M-9.5% | $32.1M-8.1% | $34.9Mn/m | $0 |
| Total Equity | $407.9M-11.0% | $458.2M-16.3% | $547.6M-6.3% | $584.1M-10.6% | $653.5M+0.5% | $650.4M+287.2% | $168.0M |
| Retained Earnings | $32.5M-61.2% | $83.8M-43.9% | $149.5M-25.2% | $199.9M-23.3% | $260.4M+2.4% | $254.4M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill.
PRTC Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$134.4Mn/m | -$105.9Mn/m | -$178.8Mn/m | -$158.3Mn/m | -$131.8Mn/m | -$98.2Mn/m | -$72.8M |
| Depreciation & Amortization | $3.6M-27.6% | $4.9M-44.5% | $8.9M+22.0% | $7.3M+9.7% | $6.6M-0.3% | $6.7M+139.9% | $2.8M |
| Capital Expenditures | $11K-84.3% | $70K-96.8% | $2.2M-60.9% | $5.6M+7.8% | $5.2M-57.4% | $12.1M+178.1% | $4.4M |
| Free Cash Flow | -$134.4Mn/m | -$106.0Mn/m | -$181.0Mn/m | -$163.8Mn/m | -$137.0Mn/m | -$110.3Mn/m | -$77.2M |
| Investing Cash Flow | $240.9M+249.2% | $69.0Mn/m | -$107.2M-154.3% | $197.4M-45.8% | $364.5M+472.5% | $63.7Mn/m | -$39.6M |
| Financing Cash Flow | -$17.0M-121.7% | $78.1Mn/m | -$29.8M-231.2% | $22.7M-41.5% | $38.9M-22.1% | $49.9M-68.2% | $156.9M |
| Share Buybacks | $4.8M-75.6% | $19.6M-25.8% | $26.5M | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid.
PRTC Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F |
|---|---|---|---|---|---|---|---|
| Net Margin | 575.4% | -2000.8% | -237.3% | -360.6% | 38.8% | 3732.7% | -340.6% |
| Return on Equity | 6.8%+21.3pp | -14.5%-7.8pp | -6.8%+4.0pp | -10.7%-11.4pp | 0.7%-55.6pp | 56.3%+98.4pp | -42.1% |
| Return on Assets | 4.6%+14.2pp | -9.6%-4.3pp | -5.3%+1.3pp | -6.6%-7.1pp | 0.5%-38.4pp | 38.9% | N/A |
| Current Ratio | 9.33+2.6x | 6.76+2.8x | 3.99+1.8x | 2.22-0.1x | 2.29+1.1x | 1.21 | N/A |
| Debt-to-Equity | 0.040.0x | 0.040.0x | 0.040.0x | 0.050.0x | 0.050.0x | 0.05+0.1x | 0.00 |
| Liabilities-to-Equity | 0.480.0x | 0.51+0.2x | 0.28-0.3x | 0.62+0.1x | 0.51+0.1x | 0.45 | N/A |
| Asset Turnover | 0.010.0x | 0.000.0x | 0.020.0x | 0.020.0x | 0.010.0x | 0.01 | N/A |
| FCF Margin | -2783.3% | -3182.8% | -1158.7% | -942.3% | -1164.2% | -1124.6% | -371.9% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| PureTech Health plc American PRTC | FY2024 | $4.8M | $27.8M | N/A | N/A | 37/100 |
| Zymeworks Inc. ZYME | FY2025 | $106.0M | -$81.1M | -76.6% | $1.8B | 79/100 |
| Spyre Therapeutics, Inc. SYRE | FY2025 | $0 | -$155.2M | N/A | $8.9B | — |
| Precigen, Inc. PGEN | FY2025 | $9.7M | -$250.6M | N/A | $1.5B | 51/100 |
| Jade Biosciences, Inc. JBIO | FY2025 | N/A | -$127.4M | N/A | $1.1B | — |
| Rigel Pharmaceuticals Inc. RIGL | FY2025 | $294.3M | $367.0M | N/A | $754.9M | 73/100 |
Where PureTech Health plc American Ranks
Frequently Asked Questions
PureTech Health plc American (PRTC) reported $4.8M in total revenue for fiscal year 2024. This represents a 45.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
PureTech Health plc American (PRTC) revenue grew by 45.0% year-over-year, from $3.3M to $4.8M in fiscal year 2024.
Yes, PureTech Health plc American (PRTC) reported a net income of $27.8M in fiscal year 2024.
As of fiscal year 2024, PureTech Health plc American (PRTC) had $280.6M in cash and equivalents against $14.7M in long-term debt.
PureTech Health plc American (PRTC) has a return on equity of 6.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
PureTech Health plc American (PRTC) recorded an outflow of $134.4M in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
PureTech Health plc American (PRTC) recorded an outflow of $134.4M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
PureTech Health plc American (PRTC) had $602.6M in total assets as of fiscal year 2024, including both current and long-term assets.
PureTech Health plc American (PRTC) invested $11K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
PureTech Health plc American (PRTC) had a current ratio of 9.33 as of fiscal year 2024, which is generally considered healthy.
PureTech Health plc American (PRTC) had a debt-to-equity ratio of 0.04 as of fiscal year 2024. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
PureTech Health plc American (PRTC) had a liabilities-to-equity ratio of 0.48 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
PureTech Health plc American (PRTC) had a return on assets of 4.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
PureTech Health plc American (PRTC) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
For every $1 of reported earnings, PureTech Health plc American (PRTC) used $4.84 of operating cash (-$134.4M OCF vs $27.8M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
PureTech Health plc American (PRTC) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.